Daniela Kandioler

Daniela Kandioler

UNVERIFIED PROFILE

Are you Daniela Kandioler?   Register this Author

Register author
Daniela Kandioler

Daniela Kandioler

Publications by authors named "Daniela Kandioler"

Are you Daniela Kandioler?   Register this Author

24Publications

485Reads

39Profile Views

Stage-directed individualized therapy in esophageal cancer.

Ann N Y Acad Sci 2016 10 6;1381(1):50-65. Epub 2016 Jul 6.

Department of Surgery, University Medical Center Utrecht, Utrecht, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/nyas.13113DOI Listing
October 2016

Fibroblast growth factor receptor 3 isoforms: Novel therapeutic targets for hepatocellular carcinoma?

Hepatology 2015 Dec 16;62(6):1767-78. Epub 2015 Oct 16.

Department of Medicine I, Division: Institute of Cancer Research, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.28023DOI Listing
December 2015

TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family.

Breast Cancer Res Treat 2015 Jun 16;151(3):671-8. Epub 2015 May 16.

Department of Surgery, Surgical Research, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-015-3424-1
Publisher Site
http://dx.doi.org/10.1007/s10549-015-3424-1DOI Listing
June 2015

Cytosine 5-Hydroxymethylation of the LZTS1 Gene Is Reduced in Breast Cancer.

Transl Oncol 2013 Dec 1;6(6):715-21. Epub 2013 Dec 1.

Molecular Diagnostics Unit, Health and Environment Department, Austrian Institute of Technology, Vienna, Austria.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890706PMC
http://dx.doi.org/10.1593/tlo.13523DOI Listing
December 2013

NORE1B is a putative tumor suppressor in hepatocarcinogenesis and may act via RASSF1A.

Cancer Res 2009 Jan;69(1):235-42

Department of Medicine I, Division: Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-08-2144DOI Listing
January 2009

HB-EGF is a paracrine growth stimulator for early tumor prestages in inflammation-associated hepatocarcinogenesis.

J Hepatol 2008 Dec 7;49(6):955-64. Epub 2008 Oct 7.

Department of Medicine I, Division: Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2008.06.031DOI Listing
December 2008

Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer.

Breast Cancer Res Treat 2007 Jul 27;103(3):283-91. Epub 2007 Jan 27.

Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-006-9377-7DOI Listing
July 2007

NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma.

J Hepatol 2006 Jul 7;45(1):81-9. Epub 2006 Feb 7.

Department of Medicine I, Division: Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2005.12.017DOI Listing
July 2006